RE:Luncheon with LucThanks bigd!
$1 Billion in sales?
I went back and looked at an SPCEO spreadsheet and he had peak sales of Ibalizumab at $250 million or so. I think CIBC is in that ballpark as well.
$1 Billion in sales would lead to huge profits and a home run share price.
For comparison, JAZZ had 1.5 Billion in revenue last year and their market cap is $8 Billion dollars!
I’m glad to hear that Lucia thinking big.
bfw
bigd1986 wrote: Conference went very well. It was a quebec finance conference, maybe 80ish people in attendance.
Luc presented very well and had a very confident tone. Below are a few interesting facts that came up during the meeting:
1. At one point Luc re-iterated a wide range of potential pricing for IBA, started off at $70k and then mentioned that typical drugs similar to IBA sell at around $140k. Later on when talking about IBA he dropped "but it will be expensive". so take that for what it's worth but i would be surprised with a price below $100k. Also mentioned that the company will help those in need afford the drug.
2. He mentioned that "in the short term" TH will be looking to acquire another drug as it only makes sense with its expanded salesforce to have more drugs to talk about.
3. He mentioned that while Taimed is a Taiwanese company, the group he deals with is located in the USA (i didnt know this)
last two points are the interesting ones:
4.Luc once again re-iterated his belief that IBA will far far exceed Egrifta in revenue. When talking about the deal with Taimed he said something along the lines of "If we hit $1bn in sales, we will be sitting pretty."
5. On more than 1 occasion he stressed that the delay in the PDUFA is PURELY related to time constraints in regards to the additional info Taimed provided the FDA. He mentioned the Thanksgiving and xmas holidays as reasons. When asked if there was any additional risk related to the delay he once again stated that it was purely a time constraint and mentioned that an approval before April is highly doable.